Implications of the incidence of influenza-like illness in nursing homes for influenza chemoprophylaxis: descriptive study
http://www.100md.com
《英国医生杂志》
1 University College London Centre for Infectious Disease Epidemiology, Department of Primary Care and Population Sciences, Royal Free Hospital, London NW3 2PF, 2 Respiratory Diseases Department, Communicable Disease Surveillance Centre, Health Protection Agency, London NW9 5EQ
Correspondence to: R Harling r.harling@pcps.ucl.ac.uk
Introduction
Giving oseltamivir prophylaxis according to the NICE guidelines would require substantial resources. Almost three quarters (35) of the homes (a total of 2004 residents) had at least one new case of ILI at some point during the four weeks in which flu activity in the community was at "normal seasonal" levels (defined in England as a weekly consultation rate for ILI of 50-200 per 100 000 population reported by the Royal College of General Practitioners' sentinel surveillance scheme3). All these residents would have been eligible for at least one course of oseltamivir during this period and might have been eligible for extended prophylaxis when ILI cases were observed in more than one week in their home.
Our weekly incidence of ILI was far higher than that reported by the sentinel scheme. This is likely to reflect the active surveillance; however, if our case definition was less specific than that used in the sentinel scheme, this also might account for the higher rate. Case definitions for flu are notoriously inaccurate, particularly in elderly people, in whom infection may present atypically.4 However, as 6% of our cases required admission to hospital and 6% died, not only mild illnesses were being recorded.
If our results applied to all 500 000 residents of nursing and residential homes in England,5 then at least 360 000 courses of oseltamivir should have been offered last winter. To be effective, oseltamivir must be given within 48 hours of exposure to infection, which requires prompt recognition of cases and rapid prescription of the drug to other residents. The drug costs ￡12.73 ($23.24; 19.30) for a seven day course—more if extended prophylaxis is required.
What is already known on this topic
National Institute for Clinical Excellence (NICE) guidelines state that oseltamivir should be given to all residents of nursing and residential homes each time a single case of influenza-like illness (ILI) is recognised in a resident or staff member and when flu is known to be circulating in the community
What this study adds
As two fifths of all nursing homes have a case of ILI every week in winter, complying with the NICE guidelines would require substantial resources
The NICE guidelines highlight the potential usefulness of oseltamivir in nursing homes. The use of a single case of ILI as the threshold for prophylaxis, however, may be impractical and costly. It might be sensible to reserve the drug for control of outbreaks when flu is microbiologically confirmed or strongly suspected on the basis of epidemiological features or local surveillance data. Further studies are needed to determine the best strategy for flu chemoprophylaxis in nursing homes.
Editorial by Jefferson and articles pp 647, 660
This article was posted on bmj.com on 27 August 2004: http://bmj.com/cgi/doi/10.1136/bmj.38204.674595.AE
Contributors: RH collected the data and wrote the paper; AH had the original idea for the study; and JMW provided additional data and expert scientific advice. RH is the guarantor. Funding: Department of Health.
Competing interests: None declared.
Ethical approval: The study has ethical approval from the London Multi-Centre Research Ethics Committee.
References
National Institute for Clinical Excellence. Technology appraisal guidance 67. Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. 2003. www.nice.org.uk/Docref.asp?d=86789 (accessed 10 Aug 2004).
Cooper NJ, Sutton AJ, Abrams KR, Allan Wailoo A, David Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326: 1235-9.
Health Protection Agency. HPA national surveillance of influenza weekly reports 2003/04. www.hpa.org.uk/infections/topics_az/influenza/fluactivity0304.htm (accessed 10 Aug 2004).
Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998;15: 16-22.
Department of Health. The residential care and nursing home sector for older people: an analysis of past trends, current and future demand. London: DoH, 2002. (Search via www.dh.gov.uk)(Richard Harling, speciali)
Correspondence to: R Harling r.harling@pcps.ucl.ac.uk
Introduction
Giving oseltamivir prophylaxis according to the NICE guidelines would require substantial resources. Almost three quarters (35) of the homes (a total of 2004 residents) had at least one new case of ILI at some point during the four weeks in which flu activity in the community was at "normal seasonal" levels (defined in England as a weekly consultation rate for ILI of 50-200 per 100 000 population reported by the Royal College of General Practitioners' sentinel surveillance scheme3). All these residents would have been eligible for at least one course of oseltamivir during this period and might have been eligible for extended prophylaxis when ILI cases were observed in more than one week in their home.
Our weekly incidence of ILI was far higher than that reported by the sentinel scheme. This is likely to reflect the active surveillance; however, if our case definition was less specific than that used in the sentinel scheme, this also might account for the higher rate. Case definitions for flu are notoriously inaccurate, particularly in elderly people, in whom infection may present atypically.4 However, as 6% of our cases required admission to hospital and 6% died, not only mild illnesses were being recorded.
If our results applied to all 500 000 residents of nursing and residential homes in England,5 then at least 360 000 courses of oseltamivir should have been offered last winter. To be effective, oseltamivir must be given within 48 hours of exposure to infection, which requires prompt recognition of cases and rapid prescription of the drug to other residents. The drug costs ￡12.73 ($23.24; 19.30) for a seven day course—more if extended prophylaxis is required.
What is already known on this topic
National Institute for Clinical Excellence (NICE) guidelines state that oseltamivir should be given to all residents of nursing and residential homes each time a single case of influenza-like illness (ILI) is recognised in a resident or staff member and when flu is known to be circulating in the community
What this study adds
As two fifths of all nursing homes have a case of ILI every week in winter, complying with the NICE guidelines would require substantial resources
The NICE guidelines highlight the potential usefulness of oseltamivir in nursing homes. The use of a single case of ILI as the threshold for prophylaxis, however, may be impractical and costly. It might be sensible to reserve the drug for control of outbreaks when flu is microbiologically confirmed or strongly suspected on the basis of epidemiological features or local surveillance data. Further studies are needed to determine the best strategy for flu chemoprophylaxis in nursing homes.
Editorial by Jefferson and articles pp 647, 660
This article was posted on bmj.com on 27 August 2004: http://bmj.com/cgi/doi/10.1136/bmj.38204.674595.AE
Contributors: RH collected the data and wrote the paper; AH had the original idea for the study; and JMW provided additional data and expert scientific advice. RH is the guarantor. Funding: Department of Health.
Competing interests: None declared.
Ethical approval: The study has ethical approval from the London Multi-Centre Research Ethics Committee.
References
National Institute for Clinical Excellence. Technology appraisal guidance 67. Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. 2003. www.nice.org.uk/Docref.asp?d=86789 (accessed 10 Aug 2004).
Cooper NJ, Sutton AJ, Abrams KR, Allan Wailoo A, David Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326: 1235-9.
Health Protection Agency. HPA national surveillance of influenza weekly reports 2003/04. www.hpa.org.uk/infections/topics_az/influenza/fluactivity0304.htm (accessed 10 Aug 2004).
Govaert TM, Dinant GJ, Aretz K, Knottnerus JA. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998;15: 16-22.
Department of Health. The residential care and nursing home sector for older people: an analysis of past trends, current and future demand. London: DoH, 2002. (Search via www.dh.gov.uk)(Richard Harling, speciali)